ACTR3B

Across TCGA pan-cancer cohorts, ACTR3B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACTR3B data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ACTR3B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACTR3B expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

UCEC, LUAD, and PDAC are the cancer types where ACTR3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.946	0.467	.002	40	view →
LUAD	OS	Quartile	II,III,IV	0.429	0.914	.004	15	view →
PDAC	OS	Tertile	II,III,IV	0.880	0.813	.017	6	view →
HNSC	DFS	Median	IV	0.916	0.652	.018	4	view →
GBM	DFS	Tertile	All	0.784	0.652	.017	3	view →
CCRCC	OS	Tertile	All	0.935	0.770	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACTR3B–UCEC (DFS)

Open the UCEC breakdown →